Differential response of microglia to distinct alpha-synuclein assemblies Article Swipe
Anke Van der Perren
,
Géraldine Gelders
,
Francesca Macchi
,
Wouter Peelaerts
,
Luc Bousset
,
Chris Van den Haute
,
Ronald Melki
,
Veerle Baekelandt
·
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.3389/conf.fnins.2017.94.00095
YOU?
·
· 2017
· Open Access
·
· DOI: https://doi.org/10.3389/conf.fnins.2017.94.00095
Event Abstract Back to Event Differential response of microglia to distinct alpha-synuclein assemblies Anke Van Der Perren1*, Géraldine Gelders1, Francesca Macchi1, Wouter Peelaerts1, Luc Bousset2, Chris Van Den Haute1, Ronald Melki2 and Veerle Baekelandt1 1 KU Leuven, Neurosciences, Belgium 2 Laboratoire d’Enzymologie et Biochimie Structurales, CNRS, France Misfolded protein aggregates are a critical aspect of several neurodegenerative diseases. There is emerging evidence that these protein aggregates can adopt distinct conformations characterized by noticeable differences in phenotypic features. The discovery of the prion-like transmissible nature of these proteins suggests a pathogenic trigger which propagate throughout the nervous system underlying the progression of the disease. In addition, there is mounting evidence that neuroinflammatory processes are closely linked to neurodegeneration during ageing. In the present study, we investigated the immunological properties of different alpha-synuclein assemblies to define the role of the innate immune system in Parkinson’s disease. We examined the microglia cell response to different recombinant alpha-synuclein assemblies via exogenous addition to primary microglia cultures. We studied uptake and degradation of the different alpha-synuclein assemblies in our primary microglial cultures by confocal microscopy and western blot. The microglial status was analyzed using qPCR and ELISA. Next, we added the microglial supernatant to primary neurons to investigate the impact of microglial priming by specific alpha-synuclein assemblies on neuronal toxicity. We showed that distinct fibrillar alpha-synuclein assemblies promote a pro-inflammatory activation of microglia, however differences between fibrillar assemblies could be observed. Oligomeric species, thought to be the primary species responsible for the disease, were unable to trigger the same cascades. These results support our hypothesis that distinct fibrillar alpha-synuclein assemblies drive the pro-inflammatory activity of microglia and represent the toxic species contributing to the disease. Keywords: alpha-Synuclein, Microglia, Parkinson's disease, Neuroinflammation, synucleinopathies Conference: 12th National Congress of the Belgian Society for Neuroscience, Gent, Belgium, 22 May - 22 May, 2017. Presentation Type: Poster Presentation Topic: Integrative Systems: Neuroendocrinology, Neuroimmunology, and Homeostatic Challenge Citation: Van Der Perren A, Gelders G, Macchi F, Peelaerts W, Bousset L, Van Den Haute C, Melki R and Baekelandt V (2019). Differential response of microglia to distinct alpha-synuclein assemblies. Front. Neurosci. Conference Abstract: 12th National Congress of the Belgian Society for Neuroscience. doi: 10.3389/conf.fnins.2017.94.00095 Copyright: The abstracts in this collection have not been subject to any Frontiers peer review or checks, and are not endorsed by Frontiers. They are made available through the Frontiers publishing platform as a service to conference organizers and presenters. The copyright in the individual abstracts is owned by the author of each abstract or his/her employer unless otherwise stated. Each abstract, as well as the collection of abstracts, are published under a Creative Commons CC-BY 4.0 (attribution) licence (https://creativecommons.org/licenses/by/4.0/) and may thus be reproduced, translated, adapted and be the subject of derivative works provided the authors and Frontiers are attributed. For Frontiers’ terms and conditions please see https://www.frontiersin.org/legal/terms-and-conditions. Received: 21 Apr 2017; Published Online: 25 Jan 2019. * Correspondence: PhD. Anke Van Der Perren, KU Leuven, Neurosciences, Leuven, Belgium, [email protected] Login Required This action requires you to be registered with Frontiers and logged in. To register or login click here. Abstract Info Abstract The Authors in Frontiers Anke Van Der Perren Géraldine Gelders Francesca Macchi Wouter Peelaerts Luc Bousset Chris Van Den Haute Ronald Melki Veerle Baekelandt Google Anke Van Der Perren Géraldine Gelders Francesca Macchi Wouter Peelaerts Luc Bousset Chris Van Den Haute Ronald Melki Veerle Baekelandt Google Scholar Anke Van Der Perren Géraldine Gelders Francesca Macchi Wouter Peelaerts Luc Bousset Chris Van Den Haute Ronald Melki Veerle Baekelandt PubMed Anke Van Der Perren Géraldine Gelders Francesca Macchi Wouter Peelaerts Luc Bousset Chris Van Den Haute Ronald Melki Veerle Baekelandt Related Article in Frontiers Google Scholar PubMed Abstract Close Back to top Javascript is disabled. Please enable Javascript in your browser settings in order to see all the content on this page.
Related Topics
Concepts
Microglia
Neurodegeneration
Alpha-synuclein
Innate immune system
Neuroprotection
Biology
Western blot
Protein aggregation
Neuroscience
Alpha (finance)
Immune system
Cell biology
Parkinson's disease
Immunology
Inflammation
Disease
Medicine
Biochemistry
Pathology
Construct validity
Patient satisfaction
Gene
Nursing
Metadata
- Type
- article
- Language
- en
- Landing Page
- https://doi.org/10.3389/conf.fnins.2017.94.00095
- OA Status
- gold
- Related Works
- 10
- OpenAlex ID
- https://openalex.org/W2914101172
All OpenAlex metadata
Raw OpenAlex JSON
- OpenAlex ID
-
https://openalex.org/W2914101172Canonical identifier for this work in OpenAlex
- DOI
-
https://doi.org/10.3389/conf.fnins.2017.94.00095Digital Object Identifier
- Title
-
Differential response of microglia to distinct alpha-synuclein assembliesWork title
- Type
-
articleOpenAlex work type
- Language
-
enPrimary language
- Publication year
-
2017Year of publication
- Publication date
-
2017-01-01Full publication date if available
- Authors
-
Anke Van der Perren, Géraldine Gelders, Francesca Macchi, Wouter Peelaerts, Luc Bousset, Chris Van den Haute, Ronald Melki, Veerle BaekelandtList of authors in order
- Landing page
-
https://doi.org/10.3389/conf.fnins.2017.94.00095Publisher landing page
- Open access
-
YesWhether a free full text is available
- OA status
-
goldOpen access status per OpenAlex
- OA URL
-
https://doi.org/10.3389/conf.fnins.2017.94.00095Direct OA link when available
- Concepts
-
Microglia, Neurodegeneration, Alpha-synuclein, Innate immune system, Neuroprotection, Biology, Western blot, Protein aggregation, Neuroscience, Alpha (finance), Immune system, Cell biology, Parkinson's disease, Immunology, Inflammation, Disease, Medicine, Biochemistry, Pathology, Construct validity, Patient satisfaction, Gene, NursingTop concepts (fields/topics) attached by OpenAlex
- Cited by
-
0Total citation count in OpenAlex
- Related works (count)
-
10Other works algorithmically related by OpenAlex
Full payload
| id | https://openalex.org/W2914101172 |
|---|---|
| doi | https://doi.org/10.3389/conf.fnins.2017.94.00095 |
| ids.doi | https://doi.org/10.3389/conf.fnins.2017.94.00095 |
| ids.mag | 2914101172 |
| ids.openalex | https://openalex.org/W2914101172 |
| fwci | 0.0 |
| type | article |
| title | Differential response of microglia to distinct alpha-synuclein assemblies |
| biblio.issue | |
| biblio.volume | 11 |
| biblio.last_page | |
| biblio.first_page | |
| topics[0].id | https://openalex.org/T10085 |
| topics[0].field.id | https://openalex.org/fields/27 |
| topics[0].field.display_name | Medicine |
| topics[0].score | 0.9926999807357788 |
| topics[0].domain.id | https://openalex.org/domains/4 |
| topics[0].domain.display_name | Health Sciences |
| topics[0].subfield.id | https://openalex.org/subfields/2728 |
| topics[0].subfield.display_name | Neurology |
| topics[0].display_name | Parkinson's Disease Mechanisms and Treatments |
| topics[1].id | https://openalex.org/T13481 |
| topics[1].field.id | https://openalex.org/fields/28 |
| topics[1].field.display_name | Neuroscience |
| topics[1].score | 0.9681000113487244 |
| topics[1].domain.id | https://openalex.org/domains/1 |
| topics[1].domain.display_name | Life Sciences |
| topics[1].subfield.id | https://openalex.org/subfields/2808 |
| topics[1].subfield.display_name | Neurology |
| topics[1].display_name | Neurological diseases and metabolism |
| topics[2].id | https://openalex.org/T10086 |
| topics[2].field.id | https://openalex.org/fields/27 |
| topics[2].field.display_name | Medicine |
| topics[2].score | 0.9657999873161316 |
| topics[2].domain.id | https://openalex.org/domains/4 |
| topics[2].domain.display_name | Health Sciences |
| topics[2].subfield.id | https://openalex.org/subfields/2737 |
| topics[2].subfield.display_name | Physiology |
| topics[2].display_name | Alzheimer's disease research and treatments |
| is_xpac | False |
| apc_list.value | 2950 |
| apc_list.currency | USD |
| apc_list.value_usd | 2950 |
| apc_paid.value | 2950 |
| apc_paid.currency | USD |
| apc_paid.value_usd | 2950 |
| concepts[0].id | https://openalex.org/C2779830541 |
| concepts[0].level | 3 |
| concepts[0].score | 0.9390696883201599 |
| concepts[0].wikidata | https://www.wikidata.org/wiki/Q1622829 |
| concepts[0].display_name | Microglia |
| concepts[1].id | https://openalex.org/C2776925932 |
| concepts[1].level | 3 |
| concepts[1].score | 0.7864151000976562 |
| concepts[1].wikidata | https://www.wikidata.org/wiki/Q1755122 |
| concepts[1].display_name | Neurodegeneration |
| concepts[2].id | https://openalex.org/C2781449126 |
| concepts[2].level | 4 |
| concepts[2].score | 0.6549225449562073 |
| concepts[2].wikidata | https://www.wikidata.org/wiki/Q288591 |
| concepts[2].display_name | Alpha-synuclein |
| concepts[3].id | https://openalex.org/C136449434 |
| concepts[3].level | 3 |
| concepts[3].score | 0.5179768800735474 |
| concepts[3].wikidata | https://www.wikidata.org/wiki/Q428253 |
| concepts[3].display_name | Innate immune system |
| concepts[4].id | https://openalex.org/C25498285 |
| concepts[4].level | 2 |
| concepts[4].score | 0.5061947703361511 |
| concepts[4].wikidata | https://www.wikidata.org/wiki/Q1981368 |
| concepts[4].display_name | Neuroprotection |
| concepts[5].id | https://openalex.org/C86803240 |
| concepts[5].level | 0 |
| concepts[5].score | 0.4839232563972473 |
| concepts[5].wikidata | https://www.wikidata.org/wiki/Q420 |
| concepts[5].display_name | Biology |
| concepts[6].id | https://openalex.org/C2776415932 |
| concepts[6].level | 3 |
| concepts[6].score | 0.4814831018447876 |
| concepts[6].wikidata | https://www.wikidata.org/wiki/Q48743 |
| concepts[6].display_name | Western blot |
| concepts[7].id | https://openalex.org/C136238340 |
| concepts[7].level | 2 |
| concepts[7].score | 0.4506174325942993 |
| concepts[7].wikidata | https://www.wikidata.org/wiki/Q7251455 |
| concepts[7].display_name | Protein aggregation |
| concepts[8].id | https://openalex.org/C169760540 |
| concepts[8].level | 1 |
| concepts[8].score | 0.4487982988357544 |
| concepts[8].wikidata | https://www.wikidata.org/wiki/Q207011 |
| concepts[8].display_name | Neuroscience |
| concepts[9].id | https://openalex.org/C64943373 |
| concepts[9].level | 4 |
| concepts[9].score | 0.4437465965747833 |
| concepts[9].wikidata | https://www.wikidata.org/wiki/Q2651003 |
| concepts[9].display_name | Alpha (finance) |
| concepts[10].id | https://openalex.org/C8891405 |
| concepts[10].level | 2 |
| concepts[10].score | 0.435647577047348 |
| concepts[10].wikidata | https://www.wikidata.org/wiki/Q1059 |
| concepts[10].display_name | Immune system |
| concepts[11].id | https://openalex.org/C95444343 |
| concepts[11].level | 1 |
| concepts[11].score | 0.36594223976135254 |
| concepts[11].wikidata | https://www.wikidata.org/wiki/Q7141 |
| concepts[11].display_name | Cell biology |
| concepts[12].id | https://openalex.org/C2779734285 |
| concepts[12].level | 3 |
| concepts[12].score | 0.3525437116622925 |
| concepts[12].wikidata | https://www.wikidata.org/wiki/Q11085 |
| concepts[12].display_name | Parkinson's disease |
| concepts[13].id | https://openalex.org/C203014093 |
| concepts[13].level | 1 |
| concepts[13].score | 0.253238320350647 |
| concepts[13].wikidata | https://www.wikidata.org/wiki/Q101929 |
| concepts[13].display_name | Immunology |
| concepts[14].id | https://openalex.org/C2776914184 |
| concepts[14].level | 2 |
| concepts[14].score | 0.23781079053878784 |
| concepts[14].wikidata | https://www.wikidata.org/wiki/Q101991 |
| concepts[14].display_name | Inflammation |
| concepts[15].id | https://openalex.org/C2779134260 |
| concepts[15].level | 2 |
| concepts[15].score | 0.19850745797157288 |
| concepts[15].wikidata | https://www.wikidata.org/wiki/Q12136 |
| concepts[15].display_name | Disease |
| concepts[16].id | https://openalex.org/C71924100 |
| concepts[16].level | 0 |
| concepts[16].score | 0.19824177026748657 |
| concepts[16].wikidata | https://www.wikidata.org/wiki/Q11190 |
| concepts[16].display_name | Medicine |
| concepts[17].id | https://openalex.org/C55493867 |
| concepts[17].level | 1 |
| concepts[17].score | 0.1431640386581421 |
| concepts[17].wikidata | https://www.wikidata.org/wiki/Q7094 |
| concepts[17].display_name | Biochemistry |
| concepts[18].id | https://openalex.org/C142724271 |
| concepts[18].level | 1 |
| concepts[18].score | 0.1405395269393921 |
| concepts[18].wikidata | https://www.wikidata.org/wiki/Q7208 |
| concepts[18].display_name | Pathology |
| concepts[19].id | https://openalex.org/C49453240 |
| concepts[19].level | 3 |
| concepts[19].score | 0.0 |
| concepts[19].wikidata | https://www.wikidata.org/wiki/Q1592163 |
| concepts[19].display_name | Construct validity |
| concepts[20].id | https://openalex.org/C2775944032 |
| concepts[20].level | 2 |
| concepts[20].score | 0.0 |
| concepts[20].wikidata | https://www.wikidata.org/wiki/Q22907659 |
| concepts[20].display_name | Patient satisfaction |
| concepts[21].id | https://openalex.org/C104317684 |
| concepts[21].level | 2 |
| concepts[21].score | 0.0 |
| concepts[21].wikidata | https://www.wikidata.org/wiki/Q7187 |
| concepts[21].display_name | Gene |
| concepts[22].id | https://openalex.org/C159110408 |
| concepts[22].level | 1 |
| concepts[22].score | 0.0 |
| concepts[22].wikidata | https://www.wikidata.org/wiki/Q121176 |
| concepts[22].display_name | Nursing |
| keywords[0].id | https://openalex.org/keywords/microglia |
| keywords[0].score | 0.9390696883201599 |
| keywords[0].display_name | Microglia |
| keywords[1].id | https://openalex.org/keywords/neurodegeneration |
| keywords[1].score | 0.7864151000976562 |
| keywords[1].display_name | Neurodegeneration |
| keywords[2].id | https://openalex.org/keywords/alpha-synuclein |
| keywords[2].score | 0.6549225449562073 |
| keywords[2].display_name | Alpha-synuclein |
| keywords[3].id | https://openalex.org/keywords/innate-immune-system |
| keywords[3].score | 0.5179768800735474 |
| keywords[3].display_name | Innate immune system |
| keywords[4].id | https://openalex.org/keywords/neuroprotection |
| keywords[4].score | 0.5061947703361511 |
| keywords[4].display_name | Neuroprotection |
| keywords[5].id | https://openalex.org/keywords/biology |
| keywords[5].score | 0.4839232563972473 |
| keywords[5].display_name | Biology |
| keywords[6].id | https://openalex.org/keywords/western-blot |
| keywords[6].score | 0.4814831018447876 |
| keywords[6].display_name | Western blot |
| keywords[7].id | https://openalex.org/keywords/protein-aggregation |
| keywords[7].score | 0.4506174325942993 |
| keywords[7].display_name | Protein aggregation |
| keywords[8].id | https://openalex.org/keywords/neuroscience |
| keywords[8].score | 0.4487982988357544 |
| keywords[8].display_name | Neuroscience |
| keywords[9].id | https://openalex.org/keywords/alpha |
| keywords[9].score | 0.4437465965747833 |
| keywords[9].display_name | Alpha (finance) |
| keywords[10].id | https://openalex.org/keywords/immune-system |
| keywords[10].score | 0.435647577047348 |
| keywords[10].display_name | Immune system |
| keywords[11].id | https://openalex.org/keywords/cell-biology |
| keywords[11].score | 0.36594223976135254 |
| keywords[11].display_name | Cell biology |
| keywords[12].id | https://openalex.org/keywords/parkinsons-disease |
| keywords[12].score | 0.3525437116622925 |
| keywords[12].display_name | Parkinson's disease |
| keywords[13].id | https://openalex.org/keywords/immunology |
| keywords[13].score | 0.253238320350647 |
| keywords[13].display_name | Immunology |
| keywords[14].id | https://openalex.org/keywords/inflammation |
| keywords[14].score | 0.23781079053878784 |
| keywords[14].display_name | Inflammation |
| keywords[15].id | https://openalex.org/keywords/disease |
| keywords[15].score | 0.19850745797157288 |
| keywords[15].display_name | Disease |
| keywords[16].id | https://openalex.org/keywords/medicine |
| keywords[16].score | 0.19824177026748657 |
| keywords[16].display_name | Medicine |
| keywords[17].id | https://openalex.org/keywords/biochemistry |
| keywords[17].score | 0.1431640386581421 |
| keywords[17].display_name | Biochemistry |
| keywords[18].id | https://openalex.org/keywords/pathology |
| keywords[18].score | 0.1405395269393921 |
| keywords[18].display_name | Pathology |
| language | en |
| locations[0].id | doi:10.3389/conf.fnins.2017.94.00095 |
| locations[0].is_oa | True |
| locations[0].source.id | https://openalex.org/S115201632 |
| locations[0].source.issn | 1662-453X, 1662-4548 |
| locations[0].source.type | journal |
| locations[0].source.is_oa | True |
| locations[0].source.issn_l | 1662-453X |
| locations[0].source.is_core | True |
| locations[0].source.is_in_doaj | True |
| locations[0].source.display_name | Frontiers in Neuroscience |
| locations[0].source.host_organization | https://openalex.org/P4310320527 |
| locations[0].source.host_organization_name | Frontiers Media |
| locations[0].source.host_organization_lineage | https://openalex.org/P4310320527 |
| locations[0].license | cc-by |
| locations[0].pdf_url | |
| locations[0].version | publishedVersion |
| locations[0].raw_type | journal-article |
| locations[0].license_id | https://openalex.org/licenses/cc-by |
| locations[0].is_accepted | True |
| locations[0].is_published | True |
| locations[0].raw_source_name | Frontiers in Neuroscience |
| locations[0].landing_page_url | https://doi.org/10.3389/conf.fnins.2017.94.00095 |
| indexed_in | crossref, doaj |
| authorships[0].author.id | https://openalex.org/A5030430979 |
| authorships[0].author.orcid | https://orcid.org/0000-0003-2924-7392 |
| authorships[0].author.display_name | Anke Van der Perren |
| authorships[0].author_position | first |
| authorships[0].raw_author_name | Anke Van Der Perren |
| authorships[0].is_corresponding | False |
| authorships[1].author.id | https://openalex.org/A5009473499 |
| authorships[1].author.orcid | https://orcid.org/0000-0003-4471-0365 |
| authorships[1].author.display_name | Géraldine Gelders |
| authorships[1].author_position | middle |
| authorships[1].raw_author_name | Géraldine Gelders |
| authorships[1].is_corresponding | False |
| authorships[2].author.id | https://openalex.org/A5044102378 |
| authorships[2].author.orcid | https://orcid.org/0000-0002-1415-8912 |
| authorships[2].author.display_name | Francesca Macchi |
| authorships[2].author_position | middle |
| authorships[2].raw_author_name | Francesca Macchi |
| authorships[2].is_corresponding | False |
| authorships[3].author.id | https://openalex.org/A5015367372 |
| authorships[3].author.orcid | https://orcid.org/0000-0003-3776-4162 |
| authorships[3].author.display_name | Wouter Peelaerts |
| authorships[3].author_position | middle |
| authorships[3].raw_author_name | Wouter Peelaerts |
| authorships[3].is_corresponding | False |
| authorships[4].author.id | https://openalex.org/A5088362192 |
| authorships[4].author.orcid | https://orcid.org/0000-0002-0433-4337 |
| authorships[4].author.display_name | Luc Bousset |
| authorships[4].author_position | middle |
| authorships[4].raw_author_name | Luc Bousset |
| authorships[4].is_corresponding | False |
| authorships[5].author.id | https://openalex.org/A5040886525 |
| authorships[5].author.orcid | https://orcid.org/0000-0002-6650-3845 |
| authorships[5].author.display_name | Chris Van den Haute |
| authorships[5].author_position | middle |
| authorships[5].raw_author_name | Chris Van Den Haute |
| authorships[5].is_corresponding | False |
| authorships[6].author.id | https://openalex.org/A5084373973 |
| authorships[6].author.orcid | https://orcid.org/0000-0003-0000-7096 |
| authorships[6].author.display_name | Ronald Melki |
| authorships[6].author_position | middle |
| authorships[6].raw_author_name | Ronald Melki |
| authorships[6].is_corresponding | False |
| authorships[7].author.id | https://openalex.org/A5081531120 |
| authorships[7].author.orcid | https://orcid.org/0000-0001-8966-2921 |
| authorships[7].author.display_name | Veerle Baekelandt |
| authorships[7].author_position | last |
| authorships[7].raw_author_name | Veerle Baekelandt |
| authorships[7].is_corresponding | False |
| has_content.pdf | False |
| has_content.grobid_xml | False |
| is_paratext | False |
| open_access.is_oa | True |
| open_access.oa_url | https://doi.org/10.3389/conf.fnins.2017.94.00095 |
| open_access.oa_status | gold |
| open_access.any_repository_has_fulltext | False |
| created_date | 2025-10-10T00:00:00 |
| display_name | Differential response of microglia to distinct alpha-synuclein assemblies |
| has_fulltext | False |
| is_retracted | False |
| updated_date | 2025-11-06T03:46:38.306776 |
| primary_topic.id | https://openalex.org/T10085 |
| primary_topic.field.id | https://openalex.org/fields/27 |
| primary_topic.field.display_name | Medicine |
| primary_topic.score | 0.9926999807357788 |
| primary_topic.domain.id | https://openalex.org/domains/4 |
| primary_topic.domain.display_name | Health Sciences |
| primary_topic.subfield.id | https://openalex.org/subfields/2728 |
| primary_topic.subfield.display_name | Neurology |
| primary_topic.display_name | Parkinson's Disease Mechanisms and Treatments |
| related_works | https://openalex.org/W2401222492, https://openalex.org/W2891888347, https://openalex.org/W2156427445, https://openalex.org/W2006645013, https://openalex.org/W2123184492, https://openalex.org/W2085209755, https://openalex.org/W1988236141, https://openalex.org/W4213266625, https://openalex.org/W2331226584, https://openalex.org/W2057089760 |
| cited_by_count | 0 |
| locations_count | 1 |
| best_oa_location.id | doi:10.3389/conf.fnins.2017.94.00095 |
| best_oa_location.is_oa | True |
| best_oa_location.source.id | https://openalex.org/S115201632 |
| best_oa_location.source.issn | 1662-453X, 1662-4548 |
| best_oa_location.source.type | journal |
| best_oa_location.source.is_oa | True |
| best_oa_location.source.issn_l | 1662-453X |
| best_oa_location.source.is_core | True |
| best_oa_location.source.is_in_doaj | True |
| best_oa_location.source.display_name | Frontiers in Neuroscience |
| best_oa_location.source.host_organization | https://openalex.org/P4310320527 |
| best_oa_location.source.host_organization_name | Frontiers Media |
| best_oa_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| best_oa_location.license | cc-by |
| best_oa_location.pdf_url | |
| best_oa_location.version | publishedVersion |
| best_oa_location.raw_type | journal-article |
| best_oa_location.license_id | https://openalex.org/licenses/cc-by |
| best_oa_location.is_accepted | True |
| best_oa_location.is_published | True |
| best_oa_location.raw_source_name | Frontiers in Neuroscience |
| best_oa_location.landing_page_url | https://doi.org/10.3389/conf.fnins.2017.94.00095 |
| primary_location.id | doi:10.3389/conf.fnins.2017.94.00095 |
| primary_location.is_oa | True |
| primary_location.source.id | https://openalex.org/S115201632 |
| primary_location.source.issn | 1662-453X, 1662-4548 |
| primary_location.source.type | journal |
| primary_location.source.is_oa | True |
| primary_location.source.issn_l | 1662-453X |
| primary_location.source.is_core | True |
| primary_location.source.is_in_doaj | True |
| primary_location.source.display_name | Frontiers in Neuroscience |
| primary_location.source.host_organization | https://openalex.org/P4310320527 |
| primary_location.source.host_organization_name | Frontiers Media |
| primary_location.source.host_organization_lineage | https://openalex.org/P4310320527 |
| primary_location.license | cc-by |
| primary_location.pdf_url | |
| primary_location.version | publishedVersion |
| primary_location.raw_type | journal-article |
| primary_location.license_id | https://openalex.org/licenses/cc-by |
| primary_location.is_accepted | True |
| primary_location.is_published | True |
| primary_location.raw_source_name | Frontiers in Neuroscience |
| primary_location.landing_page_url | https://doi.org/10.3389/conf.fnins.2017.94.00095 |
| publication_date | 2017-01-01 |
| publication_year | 2017 |
| referenced_works_count | 0 |
| abstract_inverted_index.* | 481 |
| abstract_inverted_index.- | 301 |
| abstract_inverted_index.1 | 34 |
| abstract_inverted_index.2 | 39 |
| abstract_inverted_index.R | 335 |
| abstract_inverted_index.V | 338 |
| abstract_inverted_index.a | 51, 88, 223, 396, 435 |
| abstract_inverted_index.21 | 473 |
| abstract_inverted_index.22 | 299, 302 |
| abstract_inverted_index.25 | 478 |
| abstract_inverted_index.A, | 321 |
| abstract_inverted_index.C, | 333 |
| abstract_inverted_index.F, | 325 |
| abstract_inverted_index.G, | 323 |
| abstract_inverted_index.In | 103, 119 |
| abstract_inverted_index.KU | 35, 488 |
| abstract_inverted_index.L, | 329 |
| abstract_inverted_index.To | 508 |
| abstract_inverted_index.W, | 327 |
| abstract_inverted_index.We | 144, 162, 215 |
| abstract_inverted_index.as | 395, 425, 427 |
| abstract_inverted_index.be | 234, 240, 446, 451, 501 |
| abstract_inverted_index.by | 71, 177, 208, 384, 411 |
| abstract_inverted_index.et | 42 |
| abstract_inverted_index.in | 74, 141, 172, 366, 405, 519, 607, 623, 627 |
| abstract_inverted_index.is | 59, 106, 409, 618 |
| abstract_inverted_index.of | 7, 54, 79, 84, 100, 128, 136, 167, 205, 226, 269, 291, 342, 355, 414, 430, 454 |
| abstract_inverted_index.on | 212, 634 |
| abstract_inverted_index.or | 378, 417, 510 |
| abstract_inverted_index.to | 3, 9, 115, 132, 150, 158, 198, 201, 239, 250, 277, 344, 373, 398, 500, 615, 629 |
| abstract_inverted_index.we | 123, 193 |
| abstract_inverted_index.4.0 | 439 |
| abstract_inverted_index.Apr | 474 |
| abstract_inverted_index.Den | 27, 331, 535, 556, 578, 599 |
| abstract_inverted_index.Der | 15, 319, 486, 523, 544, 566, 587 |
| abstract_inverted_index.For | 464 |
| abstract_inverted_index.Jan | 479 |
| abstract_inverted_index.Luc | 23, 531, 552, 574, 595 |
| abstract_inverted_index.May | 300 |
| abstract_inverted_index.The | 77, 183, 364, 403, 517 |
| abstract_inverted_index.Van | 14, 26, 318, 330, 485, 522, 534, 543, 555, 565, 577, 586, 598 |
| abstract_inverted_index.all | 631 |
| abstract_inverted_index.and | 31, 165, 180, 190, 271, 314, 336, 380, 401, 443, 450, 460, 467, 505 |
| abstract_inverted_index.any | 374 |
| abstract_inverted_index.are | 50, 112, 381, 387, 432, 462 |
| abstract_inverted_index.can | 66 |
| abstract_inverted_index.for | 245, 295, 359 |
| abstract_inverted_index.in. | 507 |
| abstract_inverted_index.may | 444 |
| abstract_inverted_index.not | 370, 382 |
| abstract_inverted_index.our | 173, 258 |
| abstract_inverted_index.see | 470, 630 |
| abstract_inverted_index.the | 80, 94, 98, 101, 120, 125, 134, 137, 146, 168, 195, 203, 241, 246, 252, 266, 273, 278, 292, 356, 391, 406, 412, 428, 452, 458, 632 |
| abstract_inverted_index.top | 616 |
| abstract_inverted_index.via | 155 |
| abstract_inverted_index.was | 186 |
| abstract_inverted_index.you | 499 |
| abstract_inverted_index.12th | 288, 352 |
| abstract_inverted_index.Anke | 13, 484, 521, 542, 564, 585 |
| abstract_inverted_index.Back | 2, 614 |
| abstract_inverted_index.Each | 423 |
| abstract_inverted_index.Info | 515 |
| abstract_inverted_index.May, | 303 |
| abstract_inverted_index.PhD. | 483 |
| abstract_inverted_index.They | 386 |
| abstract_inverted_index.This | 496 |
| abstract_inverted_index.been | 371 |
| abstract_inverted_index.cell | 148 |
| abstract_inverted_index.doi: | 361 |
| abstract_inverted_index.each | 415 |
| abstract_inverted_index.have | 369 |
| abstract_inverted_index.made | 388 |
| abstract_inverted_index.peer | 376 |
| abstract_inverted_index.qPCR | 189 |
| abstract_inverted_index.role | 135 |
| abstract_inverted_index.same | 253 |
| abstract_inverted_index.that | 62, 109, 217, 260 |
| abstract_inverted_index.this | 367, 635 |
| abstract_inverted_index.thus | 445 |
| abstract_inverted_index.well | 426 |
| abstract_inverted_index.were | 248 |
| abstract_inverted_index.with | 503 |
| abstract_inverted_index.your | 624 |
| abstract_inverted_index.2017. | 304 |
| abstract_inverted_index.2017; | 475 |
| abstract_inverted_index.2019. | 480 |
| abstract_inverted_index.CC-BY | 438 |
| abstract_inverted_index.CNRS, | 45 |
| abstract_inverted_index.Chris | 25, 533, 554, 576, 597 |
| abstract_inverted_index.Close | 613 |
| abstract_inverted_index.Event | 0, 4 |
| abstract_inverted_index.Gent, | 297 |
| abstract_inverted_index.Haute | 332, 536, 557, 579, 600 |
| abstract_inverted_index.Login | 494 |
| abstract_inverted_index.Melki | 334, 538, 559, 581, 602 |
| abstract_inverted_index.Next, | 192 |
| abstract_inverted_index.There | 58 |
| abstract_inverted_index.These | 255 |
| abstract_inverted_index.Type: | 306 |
| abstract_inverted_index.added | 194 |
| abstract_inverted_index.adopt | 67 |
| abstract_inverted_index.blot. | 182 |
| abstract_inverted_index.click | 512 |
| abstract_inverted_index.could | 233 |
| abstract_inverted_index.drive | 265 |
| abstract_inverted_index.here. | 513 |
| abstract_inverted_index.login | 511 |
| abstract_inverted_index.order | 628 |
| abstract_inverted_index.owned | 410 |
| abstract_inverted_index.page. | 636 |
| abstract_inverted_index.terms | 466 |
| abstract_inverted_index.there | 105 |
| abstract_inverted_index.these | 63, 85 |
| abstract_inverted_index.toxic | 274 |
| abstract_inverted_index.under | 434 |
| abstract_inverted_index.using | 188 |
| abstract_inverted_index.which | 91 |
| abstract_inverted_index.works | 456 |
| abstract_inverted_index.ELISA. | 191 |
| abstract_inverted_index.France | 46 |
| abstract_inverted_index.Front. | 348 |
| abstract_inverted_index.Google | 541, 562, 609 |
| abstract_inverted_index.Macchi | 324, 528, 549, 571, 592 |
| abstract_inverted_index.Melki2 | 30 |
| abstract_inverted_index.Perren | 320, 524, 545, 567, 588 |
| abstract_inverted_index.Please | 620 |
| abstract_inverted_index.Poster | 307 |
| abstract_inverted_index.PubMed | 584, 611 |
| abstract_inverted_index.Ronald | 29, 537, 558, 580, 601 |
| abstract_inverted_index.Topic: | 309 |
| abstract_inverted_index.Veerle | 32, 539, 560, 582, 603 |
| abstract_inverted_index.Wouter | 21, 529, 550, 572, 593 |
| abstract_inverted_index.action | 497 |
| abstract_inverted_index.aspect | 53 |
| abstract_inverted_index.author | 413 |
| abstract_inverted_index.define | 133 |
| abstract_inverted_index.during | 117 |
| abstract_inverted_index.enable | 621 |
| abstract_inverted_index.immune | 139 |
| abstract_inverted_index.impact | 204 |
| abstract_inverted_index.innate | 138 |
| abstract_inverted_index.linked | 114 |
| abstract_inverted_index.logged | 506 |
| abstract_inverted_index.nature | 83 |
| abstract_inverted_index.please | 469 |
| abstract_inverted_index.review | 377 |
| abstract_inverted_index.showed | 216 |
| abstract_inverted_index.status | 185 |
| abstract_inverted_index.study, | 122 |
| abstract_inverted_index.system | 96, 140 |
| abstract_inverted_index.unable | 249 |
| abstract_inverted_index.unless | 420 |
| abstract_inverted_index.uptake | 164 |
| abstract_inverted_index.(2019). | 339 |
| abstract_inverted_index.Article | 606 |
| abstract_inverted_index.Authors | 518 |
| abstract_inverted_index.Belgian | 293, 357 |
| abstract_inverted_index.Belgium | 38 |
| abstract_inverted_index.Bousset | 328, 532, 553, 575, 596 |
| abstract_inverted_index.Commons | 437 |
| abstract_inverted_index.Gelders | 322, 526, 547, 569, 590 |
| abstract_inverted_index.Haute1, | 28 |
| abstract_inverted_index.Leuven, | 36, 489, 491 |
| abstract_inverted_index.Online: | 477 |
| abstract_inverted_index.Perren, | 487 |
| abstract_inverted_index.Related | 605 |
| abstract_inverted_index.Scholar | 563, 610 |
| abstract_inverted_index.Society | 294, 358 |
| abstract_inverted_index.adapted | 449 |
| abstract_inverted_index.ageing. | 118 |
| abstract_inverted_index.authors | 459 |
| abstract_inverted_index.between | 230 |
| abstract_inverted_index.browser | 625 |
| abstract_inverted_index.checks, | 379 |
| abstract_inverted_index.closely | 113 |
| abstract_inverted_index.content | 633 |
| abstract_inverted_index.his/her | 418 |
| abstract_inverted_index.however | 228 |
| abstract_inverted_index.licence | 441 |
| abstract_inverted_index.nervous | 95 |
| abstract_inverted_index.neurons | 200 |
| abstract_inverted_index.present | 121 |
| abstract_inverted_index.primary | 159, 174, 199, 242 |
| abstract_inverted_index.priming | 207 |
| abstract_inverted_index.promote | 222 |
| abstract_inverted_index.protein | 48, 64 |
| abstract_inverted_index.results | 256 |
| abstract_inverted_index.service | 397 |
| abstract_inverted_index.several | 55 |
| abstract_inverted_index.species | 243, 275 |
| abstract_inverted_index.stated. | 422 |
| abstract_inverted_index.studied | 163 |
| abstract_inverted_index.subject | 372, 453 |
| abstract_inverted_index.support | 257 |
| abstract_inverted_index.thought | 238 |
| abstract_inverted_index.through | 390 |
| abstract_inverted_index.trigger | 90, 251 |
| abstract_inverted_index.western | 181 |
| abstract_inverted_index.Abstract | 1, 514, 516, 612 |
| abstract_inverted_index.Belgium, | 298, 492 |
| abstract_inverted_index.Congress | 290, 354 |
| abstract_inverted_index.Creative | 436 |
| abstract_inverted_index.Macchi1, | 20 |
| abstract_inverted_index.National | 289, 353 |
| abstract_inverted_index.Required | 495 |
| abstract_inverted_index.Systems: | 311 |
| abstract_inverted_index.abstract | 416 |
| abstract_inverted_index.activity | 268 |
| abstract_inverted_index.addition | 157 |
| abstract_inverted_index.analyzed | 187 |
| abstract_inverted_index.confocal | 178 |
| abstract_inverted_index.critical | 52 |
| abstract_inverted_index.cultures | 176 |
| abstract_inverted_index.disease, | 247, 284 |
| abstract_inverted_index.disease. | 102, 143, 279 |
| abstract_inverted_index.distinct | 10, 68, 218, 261, 345 |
| abstract_inverted_index.emerging | 60 |
| abstract_inverted_index.employer | 419 |
| abstract_inverted_index.endorsed | 383 |
| abstract_inverted_index.evidence | 61, 108 |
| abstract_inverted_index.examined | 145 |
| abstract_inverted_index.mounting | 107 |
| abstract_inverted_index.neuronal | 213 |
| abstract_inverted_index.platform | 394 |
| abstract_inverted_index.proteins | 86 |
| abstract_inverted_index.provided | 457 |
| abstract_inverted_index.register | 509 |
| abstract_inverted_index.requires | 498 |
| abstract_inverted_index.response | 6, 149, 341 |
| abstract_inverted_index.settings | 626 |
| abstract_inverted_index.species, | 237 |
| abstract_inverted_index.specific | 209 |
| abstract_inverted_index.suggests | 87 |
| abstract_inverted_index.Abstract: | 351 |
| abstract_inverted_index.Biochimie | 43 |
| abstract_inverted_index.Bousset2, | 24 |
| abstract_inverted_index.Challenge | 316 |
| abstract_inverted_index.Citation: | 317 |
| abstract_inverted_index.Francesca | 19, 527, 548, 570, 591 |
| abstract_inverted_index.Frontiers | 375, 392, 461, 504, 520, 608 |
| abstract_inverted_index.Gelders1, | 18 |
| abstract_inverted_index.Keywords: | 280 |
| abstract_inverted_index.Misfolded | 47 |
| abstract_inverted_index.Neurosci. | 349 |
| abstract_inverted_index.Peelaerts | 326, 530, 551, 573, 594 |
| abstract_inverted_index.Perren1*, | 16 |
| abstract_inverted_index.Published | 476 |
| abstract_inverted_index.Received: | 472 |
| abstract_inverted_index.abstract, | 424 |
| abstract_inverted_index.abstracts | 365, 408 |
| abstract_inverted_index.addition, | 104 |
| abstract_inverted_index.available | 389 |
| abstract_inverted_index.cascades. | 254 |
| abstract_inverted_index.copyright | 404 |
| abstract_inverted_index.cultures. | 161 |
| abstract_inverted_index.different | 129, 151, 169 |
| abstract_inverted_index.disabled. | 619 |
| abstract_inverted_index.discovery | 78 |
| abstract_inverted_index.diseases. | 57 |
| abstract_inverted_index.exogenous | 156 |
| abstract_inverted_index.features. | 76 |
| abstract_inverted_index.fibrillar | 219, 231, 262 |
| abstract_inverted_index.microglia | 8, 147, 160, 270, 343 |
| abstract_inverted_index.observed. | 235 |
| abstract_inverted_index.otherwise | 421 |
| abstract_inverted_index.processes | 111 |
| abstract_inverted_index.propagate | 92 |
| abstract_inverted_index.published | 433 |
| abstract_inverted_index.represent | 272 |
| abstract_inverted_index.toxicity. | 214 |
| abstract_inverted_index.Baekelandt | 337, 540, 561, 583, 604 |
| abstract_inverted_index.Conference | 350 |
| abstract_inverted_index.Copyright: | 363 |
| abstract_inverted_index.Frontiers. | 385 |
| abstract_inverted_index.Géraldine | 17, 525, 546, 568, 589 |
| abstract_inverted_index.Javascript | 617, 622 |
| abstract_inverted_index.Microglia, | 282 |
| abstract_inverted_index.Oligomeric | 236 |
| abstract_inverted_index.abstracts, | 431 |
| abstract_inverted_index.activation | 225 |
| abstract_inverted_index.aggregates | 49, 65 |
| abstract_inverted_index.assemblies | 12, 131, 154, 171, 211, 221, 232, 264 |
| abstract_inverted_index.collection | 368, 429 |
| abstract_inverted_index.conditions | 468 |
| abstract_inverted_index.conference | 399 |
| abstract_inverted_index.derivative | 455 |
| abstract_inverted_index.hypothesis | 259 |
| abstract_inverted_index.individual | 407 |
| abstract_inverted_index.microglia, | 227 |
| abstract_inverted_index.microglial | 175, 184, 196, 206 |
| abstract_inverted_index.microscopy | 179 |
| abstract_inverted_index.noticeable | 72 |
| abstract_inverted_index.organizers | 400 |
| abstract_inverted_index.pathogenic | 89 |
| abstract_inverted_index.phenotypic | 75 |
| abstract_inverted_index.prion-like | 81 |
| abstract_inverted_index.properties | 127 |
| abstract_inverted_index.publishing | 393 |
| abstract_inverted_index.registered | 502 |
| abstract_inverted_index.throughout | 93 |
| abstract_inverted_index.underlying | 97 |
| abstract_inverted_index.Baekelandt1 | 33 |
| abstract_inverted_index.Conference: | 287 |
| abstract_inverted_index.Homeostatic | 315 |
| abstract_inverted_index.Integrative | 310 |
| abstract_inverted_index.Laboratoire | 40 |
| abstract_inverted_index.Parkinson's | 283 |
| abstract_inverted_index.Peelaerts1, | 22 |
| abstract_inverted_index.assemblies. | 347 |
| abstract_inverted_index.attributed. | 463 |
| abstract_inverted_index.degradation | 166 |
| abstract_inverted_index.differences | 73, 229 |
| abstract_inverted_index.investigate | 202 |
| abstract_inverted_index.presenters. | 402 |
| abstract_inverted_index.progression | 99 |
| abstract_inverted_index.recombinant | 152 |
| abstract_inverted_index.reproduced, | 447 |
| abstract_inverted_index.responsible | 244 |
| abstract_inverted_index.supernatant | 197 |
| abstract_inverted_index.translated, | 448 |
| abstract_inverted_index.Differential | 5, 340 |
| abstract_inverted_index.Frontiers’ | 465 |
| abstract_inverted_index.Presentation | 305, 308 |
| abstract_inverted_index.contributing | 276 |
| abstract_inverted_index.investigated | 124 |
| abstract_inverted_index.(attribution) | 440 |
| abstract_inverted_index.Neuroscience, | 296 |
| abstract_inverted_index.Neuroscience. | 360 |
| abstract_inverted_index.Parkinson’s | 142 |
| abstract_inverted_index.Structurales, | 44 |
| abstract_inverted_index.characterized | 70 |
| abstract_inverted_index.conformations | 69 |
| abstract_inverted_index.immunological | 126 |
| abstract_inverted_index.transmissible | 82 |
| abstract_inverted_index.Neurosciences, | 37, 490 |
| abstract_inverted_index.Correspondence: | 482 |
| abstract_inverted_index.alpha-synuclein | 11, 130, 153, 170, 210, 220, 263, 346 |
| abstract_inverted_index.d’Enzymologie | 41 |
| abstract_inverted_index.Neuroimmunology, | 313 |
| abstract_inverted_index.alpha-Synuclein, | 281 |
| abstract_inverted_index.pro-inflammatory | 224, 267 |
| abstract_inverted_index.neurodegeneration | 116 |
| abstract_inverted_index.neurodegenerative | 56 |
| abstract_inverted_index.neuroinflammatory | 110 |
| abstract_inverted_index.synucleinopathies | 286 |
| abstract_inverted_index.Neuroinflammation, | 285 |
| abstract_inverted_index.Neuroendocrinology, | 312 |
| abstract_inverted_index.10.3389/conf.fnins.2017.94.00095 | 362 |
| [email protected] | 493 |
| abstract_inverted_index.(https://creativecommons.org/licenses/by/4.0/) | 442 |
| abstract_inverted_index.https://www.frontiersin.org/legal/terms-and-conditions. | 471 |
| cited_by_percentile_year | |
| countries_distinct_count | 0 |
| institutions_distinct_count | 8 |
| sustainable_development_goals[0].id | https://metadata.un.org/sdg/15 |
| sustainable_development_goals[0].score | 0.550000011920929 |
| sustainable_development_goals[0].display_name | Life in Land |
| citation_normalized_percentile.value | 0.29154352 |
| citation_normalized_percentile.is_in_top_1_percent | False |
| citation_normalized_percentile.is_in_top_10_percent | False |